logo
King Charles' Cancer Is Incurable, Bombshell Report Suggests

King Charles' Cancer Is Incurable, Bombshell Report Suggests

Yahooa day ago

King Charles' will die 'with' but not 'of' cancer, a bombshell report claimed Saturday.
The report essentially confirms long-standing rumors that the king's cancer is considered manageable but ultimately incurable, which is the case for many older individuals afflicted by the disease.
Charles is 76.
The report will be unwelcome in the palace, as it will reignite speculation that the king's health is in a delicate state, rumors that were rekindled when Prince Harry said in a recent BBC interview that he didn't know how long his father had left to live.
Charles' aides have consistently briefed reporters that he is, broadly speaking, winning his battle against cancer, and the king himself recently said he was on 'the other side' of the health crisis.
The king is back to essentially running a full diary after being diagnosed with cancer last year, albeit with some modifications.
The report, by the respected royal writer and associate editor of the U.K. Daily Telegraph, Camilla Tominey, also claimed that Charles will never move into Buckingham Palace due to his health struggles.
'The talk now is that he may die 'with' cancer, but not 'of' cancer following a rigorous treatment program,' she wrote.
A spokesperson for the king declined to comment.
Tominey, who was the first to break the news about Prince Harry and Meghan dating and also about the latter's row with Kate Middleton, added that planning for Charles' 80th birthday in 2028, while 'very tentative,' is going ahead.
Tominey also claimed that Charles and Harry could be publicly reunited at the Invictus Games, in Birmingham in 2027, with palace aides quietly investigating whether the event could provide a suitable backdrop for a long-awaited reconciliation.
It is understood officials hope any reconciliation would include Prince Archie and Princess Lilibet. The king last saw the children in 2022. Harry has said he can't bring his family safely to the U.K. and hinted some powerful palace figures want him dead.
Intriguingly, Tominey suggests that a reconciliation might be considered because of the negative impact the narrative of estrangement is having on the king's reputation.
She writes: 'There is an awareness that the impasse cannot continue forever, not least if it starts to reflect badly on the king.'
Prince Harry said, in a bitter interview with the BBC following a comprehensive legal defeat on his security arrangements, that he does not know how long his cancer-hit father has left to live because the king won't speak to him.
Harry also said he won't bring his family to the U.K., blamed his father for his security being reduced after leaving the royal family, and said he had 'forgiven' those family members who had hurt him.
He added, 'Some members of my family will never forgive me for writing a book but I would love reconciliation with my family.'
The prince continued, 'There is a lot of control and ability in my father's hands. Ultimately, this whole thing could be resolved through him.'
Appearing emotional, Harry said, ​'There's no point in continuing to fight anymore. As I said, life is precious. I don't know how much longer my father has. He won't speak to me because of this security stuff, but it would be nice to reconcile.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mavacamten Showing Real-World Success in Treating oHCM
Mavacamten Showing Real-World Success in Treating oHCM

Medscape

time22 minutes ago

  • Medscape

Mavacamten Showing Real-World Success in Treating oHCM

MANCHESTER — Mavacamten (Camzyos, Bristol Myers Squibb) continues to show promising results in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a consultant cardiologist said at the recent British Cardiovascular Society Annual Conference 2025. William Jenkins, a consultant cardiologist at the Royal Infirmary of Edinburgh, said that real world outcomes mirror those from clinical trials, including EXPLORER and VALOR-HCM. High Rates of Symptom Improvement Notably, data from three UK centres showed that about 70%-80% of patients experienced symptomatic improvement with mavacamten treatment. In addition, 90% saw a 30mmHg drop in the left ventricular outflow tract (LVOT) gradient – considered a significant reduction in obstruction. William Jenkins Although patients initially required 'very intense echocardiographic surveillance', Jenkins said 'it gets much easier' after the first few months of treatment. 'I think our reliance upon echocardiography will probably reduce as we get more experience with this,' he told Medscape News UK . A First-in-Class Therapy Mavacamten, a cardiac myosin inhibitor, is the first drug of its kind. It works by normalising contractility, reducing dynamic LVOT obstruction, and improving cardiac filling pressures in people with HCM. 'HCM is something that develops over decades,' Jenkins said. 'You can develop symptoms early, but you can have those symptoms for a really long time before you go on to develop other things like abnormal heart rhythms, heart failure, or dying suddenly.' He added that although oHCM is considered rare, many patients could benefit from treatment. Managing HCM still falls within general cardiology in some centres, Jenkins noted, raising concerns that patients may not be reviewed as frequently as needed. 'People live with it for years and years — if not decades — before they develop any of the end stage features of HCM,' Jenkins said. 'They can become very adapted to their symptoms.' Patient Advocacy and Experience Hypertrophic cardiomyopathy affects around 1 in 500 people in the UK and US, with about two thirds of cases involving obstruction. Katharine McIntosh, head of research and policy at Cardiomyopathy UK, told Medscape News UK that mavacamten had been a 'cause for excitement' among patients. 'It's the first big cardiomyopathy-specific drug.' McIntosh expressed frustration at the slow rollout of the drug, which was recommended for NHS use in England and Wales in 2023 and in Scotland in 2024. 'It's at the point now where one would have thought that everyone who should be on it would be getting onto it. But that's just not been the case,' she said. A recent Cardiomyopathy UK survey found that patients who accessed mavacamten were 'very positive' about its effects. Respondents described it as 'life changing' and felt like they had been given their lives back, McIntosh said. Challenges Facing Widespread Use One barrier is that mavacamten must be prescribed and monitored by specialists experienced in treating cardiomyopathies – resources not available at all centres. Prescribing guidance states that patients require echocardiography before and at regular intervals after starting treatment. Genetic testing for Cytochrome P450 (CYP) 2C19 (CYP2C19) is also needed to guide dosing. Long-Term Outlook Jenkins said that three key issues must be considered before prescribing mavacamten: Close early monitoring is needed, as the drug can cause left ventricular systolic dysfunction. CYP2C19-related drug interactions require pharmacy input. Counselling is essential due to potential foetal toxicity risks. 'Most people tolerate this [drug] very well', he said. After the initial 12-week period, follow-up can be reduced to every 3-6 months. 'This is an indefinite medication for a lot of people' Jenkins said. However, with an estimated annual cost of almost £14,000 per patient, he stressed the need for careful initial use. 'Right now, the indication is for symptomatic, severe LVOT obstruction,' he said. However, 'there's no reason in the long-term why this shouldn't become first-line'. Whether mavacamten offers benefit for oHCM patients without obstruction remains unclear. Jenkins has acted as a consultant to BMS and AstraZeneca. McIntosh had no conflicts of interest to disclose.

Fox News Entertainment Newsletter: Madonna name-dropped in Diddy trial, Miley Cyrus turns heads in sheer dress
Fox News Entertainment Newsletter: Madonna name-dropped in Diddy trial, Miley Cyrus turns heads in sheer dress

Fox News

time36 minutes ago

  • Fox News

Fox News Entertainment Newsletter: Madonna name-dropped in Diddy trial, Miley Cyrus turns heads in sheer dress

Welcome to the Fox News Entertainment Newsletter. TOP 3: -Madonna, Leonardo DiCaprio name-dropped in Diddy's federal trial amid explosive testimony -Miley Cyrus drips in crystals as she turns heads in a risqué sheer dress -Kate Middleton stands firm with Prince William as doors 'shut' on Prince Harry: expert GIRL NEXT DOOR - Former Playboy model confesses major missed opportunity during years with Hugh Hefner. BOLD MOVE - Hailey Bieber flaunts curves in bikini photos as fans praise cheeky Rhode placement. MAJOR RULING - Justin Baldoni's $400M lawsuit against Blake Lively dismissed. SPLIT FOCUS - Meghan Markle reportedly 'wishes' Prince Harry would stop dwelling on the past. ON THE RECORD - Diddy's ex reveals he still pays her rent while testifying about alleged abuse. GROWING PAINS - Ron Howard's daughter had a 'messed-up' childhood fixation that worried her parents. 'LAST LINE' - 'American Pie' star Jason Biggs admits digging through trash for cocaine during drug addiction. LIKE WHAT YOU'RE READING? CLICK HERE FOR MORE ENTERTAINMENT NEWS FOLLOW FOX NEWS ON SOCIAL MEDIA

Kate Middleton Embraces Power Dressing in Blue McQueen Suit for Museum Visit
Kate Middleton Embraces Power Dressing in Blue McQueen Suit for Museum Visit

Yahoo

timean hour ago

  • Yahoo

Kate Middleton Embraces Power Dressing in Blue McQueen Suit for Museum Visit

Kate Middleton stepped out for a solo public appearance during a visit to the Victoria & Albert museum in London on Tuesday. The Princess of Wales met with Tristram Hunt, director of the V&A, and other distinguished personnel during her tour of the museum. For her daytime outing, Middleton favored one of her go-to designers, wearing a look courtesy of McQueen. The British royal family member styled a crepe jacket in electric blue and cigarette wool trousers in the same shade of blue courtesy of McQueen. More from WWD Prada Group Creates Trust Fund With UNESCO for Sea Beyond Project Queen Letizia of Spain Favors Classic Black and White Colorblocking in Massimo Dutti for Public Engagement in Madrid Katie Holmes Goes for Color Contrast in Prada, Danielle Brooks Shines in Stephane Rolland and More Looks From the 2025 Tony Awards The Princess of Wales coordinated the look with a cotton blend puff sleeve top in white by American designer Ralph Lauren. She also wore a pair of pointed-toe suede pumps in navy by Prada. Middleton added a black belt to her attire as well. As for her jewelry pieces, Middleton wore a pair of blue lapis and moonstone earrings by London-based label Carousel Jewels. She added another piece with her yellow gold necklace courtesy of New York City-based designer Laura Lombardi. McQueen has long been a favorite label of the Princess of Wales. The British royal's April 2011 wedding dress, worn for her nuptials at Westminster Abbey, was designed by former McQueen creative director Sarah Burton. The designer left the fashion house in 2023 for an appointment as the creative director of Givenchy. Middleton's latest look not only highlights one of her preferred designers, but also a style that's grown in popularity among contemporary royal women. The Princess of Wales has often incorporated power dressing and suited looks into her royal wardrobe, styling pieces by Burberry, Roland Mouret and more designers. The power suit for royal women has deep roots, dating to Princess Diana's memorable Catherine Walker suited moment and Hackett waistcoat from 1988. In the decades since, women like Queen Letizia of Spain, Meghan Markle, Queen Mary of Denmark and more have styled power suiting moments, specifically for daytime occasions. View Gallery Launch Gallery: Kate Middleton's Style Through the Years: Burberry Suits, Alexander McQueen Dresses & More Best of WWD Mia Threapleton's Red Carpet Style Through the Years [PHOTOS] Princess Charlene of Monaco's Grand Prix Style Through the Years: Louis Vuitton, Akris and More, Photos Princess Charlene's Monaco Grand Prix Style Evolution at Full Speed: Shades of Blue in Louis Vuitton, Playful Patterning in Akris and More

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store